Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males.

Biopharmaceutics & drug disposition - 1 Jan 2012

Hakooz Nancy, Salem Isam I

Abstract excerpt

PURPOSE: To study the prevalence of desloratadine slow metabolizer phenotype among a group of healthy Jordanian male volunteers. METHODS: A total of 62 healthy Jordanian male volunteers were included in this study. A single 5 mg desloratadine oral tablet was given and blood samples were taken to determine the desloratadine and 3-hydroxydesloratadine (3-OH-desloratadine) concentrations using a specific liquid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Area Under Curve
Share to Chromatography, High Pressure Liquid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Jordan

Share to Phenotype

Share to Tandem Mass Spectrometry

Share to Young Adult

Source

Identifiers

PMID: 22271705
DOI: 10.1002/bdd.1770

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males.PMID 22271705Read ↗

Prevalence of Desloratadine Slow-metabolizer Phenotype and Food-dependent Pharmacokinetics of Desloratadine in Healthy Chinese Volunteers.Semantic proximity Read ↗

Possible interethnic differences in omeprazole pharmacokinetics : comparison of Jordanian Arabs with other populations.Semantic proximity Read ↗

Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites-a study in 839 patients with known CYP2D6 genotype.Semantic proximity Read ↗

Dextromethorphan O-demethylation polymorphism in Jordanians.Semantic proximity Read ↗

Assessment of tramadol pharmacokinetics in correlation with CYP2D6 and clinical symptoms.Semantic proximity Read ↗

Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.Semantic proximity Read ↗

A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers.Semantic proximity Read ↗

Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies.Semantic proximity Read ↗

Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.Semantic proximity Read ↗

Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.Semantic proximity Read ↗

Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians.Semantic proximity Read ↗

N-acetylation phenotyping using dapsone in a Jordanian population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.